6-甲氧基-4-氧代-1H-喹啉-7-羧酸甲酯 | 863786-19-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-甲氧基-4-氧代-1H-喹啉-7-羧酸甲酯
• 中文别名: 6-甲氧基-4-氧代-1,4-二氢喹啉-7-羧酸甲酯
• 英文名称: methyl 6-methoxy-4-oxo-1H-quinoline-7-carboxylate
• 英文别名: 6-methoxy-7-methoxycarbonyl-1,4-dihydroquinolin-4-one；Methyl 6-methoxy-4-oxo-1,4-dihydroquinoline-7-carboxylate
• CAS: 863786-19-0
• 化学式: C₁₂H₁₁NO₄
• 分子量: 233.224
• InChiKey: GUFWOLGMEYBTHR-UHFFFAOYSA-N

物化性质

• 沸点：
  421.0±45.0 °C(Predicted)
• 密度：
  1.267±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  6-甲氧基-4-氧代-1H-喹啉-7-羧酸甲酯 在 甲醇 、 lithium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 16.0h， 生成 6-甲氧基-4-氧代-1,4-二氢喹啉-7-羧酸
  参考文献：
  名称：

  WO2007/99326

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 5-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methylamino]-2-methoxybenzoate 以 二苯醚 、 联苯 为溶剂， 反应 0.75h， 生成 6-甲氧基-4-氧代-1H-喹啉-7-羧酸甲酯
  参考文献：
  名称：

  EP1724268

  摘要：

  公开号：

文献信息

• QUINOLINE DERIVATIVES
  申请人：Jung Frederic Henri

  公开号：US20090076075A1

  公开（公告）日：2009-03-19

  The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  这项发明涉及公式I的喹啉衍生物或其药用盐，其中X 1 ，p，R 1 ，q，R 2 ，R 3 ，R 4 ，R 5 ，环A，r和R 6 中的每一个具有在描述中定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱的药物的药物中的使用。
• Quinoline derivatives
  申请人：AstraZeneca AB

  公开号：US07973164B2

  公开（公告）日：2011-07-05

  The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  本发明涉及式I的喹啉衍生物或其药学上可接受的盐，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有本说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖性疾病的药物中的使用。
• Strategic studies in the syntheses of novel 6,7-substituted quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones
  作者：Rémy Morgentin、Georges Pasquet、Pascal Boutron、Frédéric Jung、Maryannick Lamorlette、Mickaël Maudet、Patrick Plé

  DOI：10.1016/j.tet.2008.01.055

  日期：2008.3

  This paper describes the different strategies devised and applied to overcome the selectivity issues in the syntheses of 6,7-disubstituted-1H-quinolin-4-one, 7-substituted-1H-1,6-naphthyridin-4-one and 6-substituted-1H-1,7-naphthyridin-4-one derivatives. They allowed us to improve the overall yields and the scating-up feasibility. Several examples illustrate these strategies with their advantages and drawbacks. (C) 2008 Elsevier Ltd. All rights reserved.
• COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
  申请人：Exelixis, Inc.

  公开号：EP3743070A1

  公开（公告）日：2020-12-02
• Compounds for the Treatment of Kinase-Dependent Disorders
  申请人：Exelixis, Inc.

  公开号：US20210040076A1

  公开（公告）日：2021-02-11

  Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.